🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

67 results for “ADC” Clear

  1. DS-8201a, Kadcyla 100 mg powder for concentrate for solution for infusion.

    Daiichi Sankyo Europe GmbH

    Metastatic breast cancer

    phase 3 small molecule active

    1 trial

  2. DS-8201a, Kadcyla 100 mg powder for concentrate for solution for infusion., Kadcyla 160 mg powder for concentrate for solution for infusion.

    Daiichi Sankyo Europe GmbH

    High-Risk HER2-Positive Breast Cancer

    phase 3 small molecule active

    1 trial

  3. DURVALUMAB, MYCOPHENOLIC ACID , Padcev 20 mg powder for concentrate for solution for infusion, TREMELIMUMAB, Padcev 30 mg powder for concentrate for solution for infusion, INFLIXIMAB

    AstraZeneca AB

    Bladder Cancer

    phase 3 small molecule active

    1 trial

  4. Doxorubicinhydrochlorid Teva® 2 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bleomycin 15000 IU Powder for solution for injection/infusion, Detimedac 200 mg, Pulver zur Herstellung einer Injektions-/Infusionslösung, Doxorubicin hydrochloride 2 mg/ml solution for infusion, ADCETRIS 50 mg powder for concentrate for solution for infusion, Vinblastine Sulfate 1 mg/ml solution for injection, Dacarbazine medac 200 mg, powder for solution for injection/infusion, Vinblastinsulfat Teva® 1 mg/ml Injektions

    Takeda Pharmaceuticals International AG

    Advanced Classical Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  5. Household-based water treatment with NADCC tablets

    United Therapeutics Europe Ltd

    Diarrhoea

    phase 3 other completed

    1 trial

  6. Loncastuximab Tesirine

    ADC Therapeutics SA

    Relapsed Diffuse Large B-Cell Lymphoma

    phase 3 small molecule active

    1 trial

  7. Odronextamab

    ADC Therapeutics SA

    B-cell Non Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  8. Phesgo 1200 mg/600 mg solution for injection, Perjeta 420 mg concentrate for solution for infusion, Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, Phesgo 600 mg/600 mg solution for injection

    Fondazione Telethon ETS

    Invasive Breast Cancer

    phase 3 small molecule active

    1 trial

  9. Phesgo 600 mg/600 mg solution for injection, Herceptin 600 mg solution for injection in vial, Perjeta 420 mg concentrate for solution for infusion, Phesgo 1200 mg/600 mg solution for injection, Kadcyla 160 mg powder for concentrate for solution for infusion.

    Roche Registration Limited

    Early or Locally Advanced/ Inflammatory HER2-Positive Breast Cancer

    phase 3 small molecule active

    1 trial

  10. Placebo ADCETRIS ( NaCl 0.9% 100 mL - Injection IV ), ADCETRIS 50 mg powder for concentrate for solution for infusion.

    Pari Pharma GmbH

    rare disease

    phase 3 small molecule active

    1 trial

  11. Tecentriq 1 200 mg concentrate for solution for infusion, Herceptin 600 mg solution for injection in vial, Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq placebo

    Roche Registration Limited

    Early human epidermal growth factor receptor 2 (HER2) positive breast cancer

    phase 3 small molecule active

    1 trial

  12. AAV2-hAADC

    PTC THERAPEUTICS, INC.

    Aromatic Amino Acid Decarboxylase Deficiency

    phase 2 small molecule completed

    1 trial

  13. ADCETRIS 50 mg powder for concentrate for solution for infusion

    Takeda Pharmaceuticals International AG

    Hodgkin lymphoma (HL) - Hodgkin lymphoma (HL), a neoplasm of lymphoid tissue which is histopathologically defined by the presence of malignant Hodgkin Reed-Sternberg (HRS) cells in a background of inflammatory cells. The proposed pediatric study has been designed to evaluate brentuximab vedotin as a component of a multiagent frontline chemotherapy regimen in patients with advanced stage, newly diagnosed HL, here defined as Stage III and Stage IV and a ≥50 Lansky Play-Performance or Karnofsky Performance Status.

    phase 2 small molecule active

    1 trial

  14. ADCETRIS 50 mg powder for concentrate for solution for infusion, DACARBAZINE , DOXORUBICIN , DEXAMETHASONE , VINBLASTINE , CYCLOPHOSPHAMIDE , ETOPOSIDE

    Cancer Prevention Pharma (Ireland) Limited

    Advanced stage Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  15. ADCT-301

    ADC Therapeutics SA

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule terminated

    1 trial

  16. ADCT-602

    ADC Therapeutics SA

    Blasts 5 Percent or More of Bone Marrow Nucleated Cells

    phase 2 mab terminated

    1 trial

  17. Adcetris-Levact

    Takeda Pharmaceuticals International AG

    Clinical Efficacy

    phase 2 small molecule completed

    1 trial

  18. An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer

    Eisai GmbH

    HER2 positive or HER2-low metastatic breast cancer

    phase 2 other active

    1 trial

  19. Avastin 25 mg/ml concentrate for solution for infusion., Lynparza 150 mg film-coated tablets, Cotellic 20 mg film-coated tablets, Ipatasertib, Cotellic, Cotellic, INAVOLISIB, Sindaxel 6 mg/ml concentrat pentru soluţie perfuzabilă, Verzenios 50 mg film-coated tablets, Cotellic, Lynparza 100 mg film-coated tablets, Kadcyla 160 mg powder for concentrate for solution for infusion., LETRO-cell® 2,5 mg Filmtabletten, INAVOLISIB, Verzenios 100 mg film-coated tablets, INAVOLISIB, Lynparza 150 mg film-coated tablets

    Roche Registration Limited

    Persistent or Recurrent Rare Epithelial Ovarian Tumors

    phase 2 small molecule active

    1 trial

  20. CETUXIMAB, FOLINIC ACID, FLUOROURACIL, IRINOTECAN

    Fondazione Telethon ETS

    ADCC, Colorectal Cancer

    phase 2 small molecule active

    1 trial

  21. Camidanlumab Tesirine

    ADC Therapeutics SA

    Relapsed Hodgkin Lymphoma

    phase 2 small molecule completed

    1 trial

  22. Cyclophosphamide

    ADC Therapeutics SA

    Double-Expressor Lymphoma

    phase 2 small molecule active

    1 trial

  23. Eladocagene Exuparvovec

    PTC THERAPEUTICS, INC.

    AADC Deficiency

    phase 2 gene therapy active

    1 trial

  24. Epcoritamab

    ADC Therapeutics SA

    Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources